Elanco Animal HealthELAN +0.81%66 Net Current Asset Value is $-6.28 as of Mar. 2026. GuruFocus rates ELAN with a GF Score™ of 66/100 and a GF Value™ of $15.59 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 611 Drug Manufacturers companies, Elanco Animal Health ranks worse than 163665.96% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Elanco Animal Health's net current asset value per share for the quarter that ended in Mar. 2026 was $-6.28.
The historical rank and industry rank for Elanco Animal Health's Net Current Asset Value or its related term are showing as below:
During the past 11 years, the highest Price-to-Net-Current-Asset-Value Ratio of Elanco Animal Health was 159.93. The lowest was 159.93. And the median was 159.93.
ELAN's Price-to-Net-Current-Asset-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.71 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Elanco Animal Health (NYSE:ELAN) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Elanco Animal Health Net Current Asset Value Related Terms
Elanco Animal Health Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Elanco Animal Health's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elanco Animal Health Net Current Asset Value Chart
ELAN vs ALKS, HIMS, NBIX: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elanco Animal Health's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elanco Animal Health Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elanco Animal Health's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Elanco Animal Health's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $-6.28 mean?
Elanco Animal Health (ELAN) has a Net Current Asset Value of $-6.28 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Elanco Animal Health and its competitors. Over the past decade, Elanco Animal Health's Net Current Asset Value has ranged from 159.93 to 159.93. According to the industry distribution chart, Elanco Animal Health ranks #999999 out of 611 companies in the Drug Manufacturers industry.
Is Elanco Animal Health's Net Current Asset Value too high?
Elanco Animal Health's current Net Current Asset Value is $-6.28. Over the past 10 years, this metric has ranged from a low of 159.93 to a high of 159.93. Based on the distribution chart, Elanco Animal Health ranks #999999 out of 611 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Elanco Animal Health has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Elanco Animal Health's Net Current Asset Value compare to ALKS and HIMS?
According to the Drug Manufacturers industry distribution chart, Elanco Animal Health ranks #999999 out of 611 companies for Net Current Asset Value. This places Elanco Animal Health in the lower half of its industry. The industry median Net Current Asset Value is 5.71. Historically, Elanco Animal Health's own Net Current Asset Value has ranged from 159.93 to 159.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.71, based on 611 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Elanco Animal Health and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elanco Animal Health's current Net Current Asset Value is $-6.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elanco Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Elanco Animal Health (ELAN) is currently considered Significantly Overvalued. The stock's GF Value™ is $15.59, compared to a current price of $24.82 — trading 59.2% above its estimated fair value. The current Net Current Asset Value is $-6.28. Elanco Animal Health's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Elanco Animal Health (ELAN), the current Net Current Asset Value is $-6.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elanco Animal Health (ELAN) Overvalued in 2026?
Based on GuruFocus' analysis, Elanco Animal Health stock appears to be overvalued.
The current stock price of $24.82 is trading 59.2% above its estimated GF Value™ of $15.59.
GuruFocus considers Elanco Animal Health to be Significantly Overvalued.
Key valuation signals for ELAN:
Net Current Asset Value: $-6.28
GF Value™: $15.59 vs. price of $24.82 (59.2% above fair value)
No single metric tells the full story. See the ELAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
66GF Score
Get the complete analysis for ELAN
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELAN has been successfully added to your 
